The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Eli Lilly's revenues will wither -8.5% and EPS will drop -27.4%.
The average estimate for revenue is $5.62 billion. On the bottom line, the average EPS estimate is $0.82.
Last quarter, Eli Lilly chalked up revenue of $5.60 billion. GAAP reported sales were 10% lower than the prior-year quarter's $6.25 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.83. GAAP EPS of $0.83 for Q2 were 22% lower than the prior-year quarter's $1.07 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 79.5%, 90 basis points worse than the prior-year quarter. Operating margin was 21.5%, 600 basis points worse than the prior-year quarter. Net margin was 16.5%, 260 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $22.70 billion. The average EPS estimate is $3.39.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,255 members out of 1,353 rating the stock outperform, and 98 members rating it underperform. Among 411 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 389 give Eli Lilly a green thumbs-up, and 22 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eli Lilly is hold, with an average price target of $39.03.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Eli Lilly. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Eli Lilly to My Watchlist.